Palombo, Turner, Campos, Andrea, Vernon, Suzanne D et al. · Journal of translational medicine · 2020 · DOI
Researchers developed a wearable sensor that measures how much time ME/CFS patients spend standing or walking each day (called UpTime). In a small study of 15 people, they found that severely ill ME/CFS patients spend less than 20% of their day upright, moderately ill patients spend 20-30%, while healthy people spend more than 30%. This sensor measurement was more accurate than asking patients to estimate their activity themselves, suggesting it could be a reliable way to track disease severity and test new treatments.
ME/CFS lacks objective biomarkers for assessing disease severity and treatment response, forcing clinicians to rely on patient reports which may be inaccurate. An objective, wearable sensor measure could standardize disease assessment, enable better treatment monitoring, and provide reliable endpoints for clinical trials—potentially accelerating development of effective therapies.
This small pilot study does not establish UpTime as a definitive diagnostic tool or confirm its validity across diverse ME/CFS populations. The 6-day monitoring period may not capture long-term patterns or post-exertional malaise cycles. The findings cannot yet be generalized beyond this specific sample and require validation in larger, multi-center studies before clinical implementation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.